



**MERZ NORTH AMERICA ANNOUNCES
CLINICAL DATA PRESENTATIONS AT THE
2015 WORLD CONGRESS OF DERMATOLOGY**

RALEIGH, N.C. – JUNE 9, 2015 – BUSINESS WIRE – [Merz North America](#), US affiliate of the global Merz Pharma Group, announced today that ten poster presentations have been accepted by the [23rd World Congress of Dermatology](#), which is being held in Vancouver, Canada from June 8-13, 2015. The data being presented is representative of all of Merz's North American business units and includes research on products across the Merz portfolio.

“As a privately-held and family-owned company, Merz is proud to bring a consistent, long-term focus to the key specialties that we serve,” said Bill Humphries, President and CEO of Merz North America. “We remain committed to investing in a product and program pipeline that will continue to expand the treatment options available to patients and physicians in aesthetics and medical dermatology.”

The below ePosters will be available for viewing in the WCD 2015 International Poster Gallery throughout the meeting.

1. **A Multicentre Retrospective Chart Review of Patients Converted from OnabotulinumtoxinA to IncobotulinumtoxinA for Aesthetic Treatments to Evaluate Injection Intervals and Doses Used.** Alfred Balbul, Rob Miller, et al. Poster # 2981743. FEATURE POSTER DISPLAY Friday, 6/12/2015 from 9:00:00 AM to 1:00:00 PM.
2. **Calcium Hydroxylapatite with Integral Lidocaine for the Correction of Nasolabial Folds: A Covariate Safety and Effectiveness Analysis.** Daniel Schachter, Vince Bertucci, and Nowell Solish. Poster # 2983259. E-POSTER PRESENTATION
3. **Hand Function Evaluation Following Calcium Hydroxylapatite Hand Treatment.** Vince Bertucci and Nowell Solish. Poster # 2983112. E-POSTER PRESENTATION
4. **Prospective Evaluation of Calcium Hydroxylapatite in the Management of Jawline Aesthetics.**¹ Andreas Nikolis and Arthur Swift. Poster # 2981950. E-POSTER PRESENTATION
5. **Validation of a New Visual Scale to Assess the Cohesivity of Crosslinked Hyaluronic Acid Soft Tissue Fillers and Evaluation of Ten Fillers.**¹ Hema Sundaram and Samuel Gavard Molliard. Poster # 2983188. E-POSTER PRESENTATION

¹ Investigator-initiated study

6. **Matrikine-Based Micro-Protein Complex Technology For Skin Rejuvenation.** Frank Dreher and Michael H. Gold. Poster # 2981680 E-POSTER PRESENTATION
7. **Prospective, Multi-Center, Pivotal Trial Evaluating the Safety and Effectiveness of Microfocused Ultrasound with Visualization (MFU-V) for Improving Lines and Wrinkles of the Décolletage.** Michael H. Gold, Sabrina G. Fabi, et al. Poster #2878091 E-POSTER PRESENTATION
8. **Prospective, Single-site, Single-blinded, Randomized, Split-body Pilot Study of the Safety and Effectiveness of Microfocused Ultrasound with Visualization (MFU-V) for Lifting of the Buttock.** Sabrina Fabi, Mitchel Goldman, et al. Poster # 3086446 E-POSTER PRESENTATION
9. **Naftifine Hydrochloride 2% Cream and 39% Urea Cream For the Treatment of Tinea Pedis Complicated by Hyperkeratosis.**¹ Leon Kircik and Neh Onumah. Poster # 2981573 E-POSTER PRESENTATION
10. **Clinical Benefit and Assessment of Pharmacokinetic Profile of Naftifine Hydrochloride Cream 2%: An Open-Label, Multicenter, Multiple Application Study in Pediatric Subjects with Tinea Pedis and Tinea Cruris.** Amit Verma. Poster # 2969455 E-POSTER PRESENTATION

About Merz North America

Merz North America is a specialty healthcare company that develops and commercializes innovative, high-quality treatment solutions in aesthetics, dermatology and neurosciences in the U.S. and Canada. As part of the Merz Pharma Group of companies, our ambition is to become the most admired, trusted and innovative aesthetics and neurotoxin company. By developing products that improve patients' health and help them to live better, feel better and look better, we will continue to make significant contributions to the well-being of individuals around the world. With the acquisitions of **NEOCUTIS** and **Ulthera**, Merz is building an aesthetics portfolio with a range of treatment options (device, injectables and topicals) that allow physicians to use Merz technologies to treat a broader range of patients and concerns. Merz is also an important contributor to the U.S. dermatology space, offering a well-balanced product portfolio that includes Naftin[®] (naftifine HCl), the #1 topical antifungal brand prescribed by dermatologists and podiatrists in the U.S. To learn more about Merz's full portfolio, please visit www.merzusa.com.

Corporate Contact:

Mariana Smith Bourland
Merz North America
6501 Six Forks Road
Raleigh, NC 27615
Cell (336) 339-0172
Mariana.Smith@merz.com